Nurix Therapeutics

General Information
Business:

 

We are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging our extensive expertise in E3 ligases together with our proprietary DNA-encoded libraries, we have built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Our drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system, or UPS, to selectively decrease or increase cellular protein levels. 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 103
Founded: 2009
Contact Information
Address 1700 Owens Street, Suite 205, San Francisco, CA 94158, US
Phone Number (415) 660-5320
Web Address http://www.nurixtx.com
View Prospectus: Nurix Therapeutics
Financial Information
Market Cap $648.1mil
Revenues $19.5 mil (last 12 months)
Net Income $-20.8 mil (last 12 months)
IPO Profile
Symbol NRIX
Exchange NASDAQ
Shares (millions): 11.0
Price range $19.00 - $19.00
Est. $ Volume $209.0 mil
Manager / Joint Managers J.P. Morgan/ Piper Sandler/ Stifel
CO-Managers Needham & Company
Expected To Trade: 7/24/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change